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Abstract: Cardiogenic shock continues to be the most common cause of death in patients hospitalized with acute myocar-
dial infarction. It has also been frequently associated with ST-segment elevation myocardial infarction (STEMI) and pa-
tients with co-morbidities. Cardiogenic shock presents with low systolic blood pressure and clinical signs of hypoperfu-
sion. Rapid diagnosis and supportive therapy in the form of medications, airway support and intra-aortic balloon counter-
pulsation is required. Initial stabilization can be followed by reperfusion by fibrinolytic therapy, emergent percutaneous 
intervention (PCI) or coronary artery bypass grafting (CABG). The latter two have been found to decrease mortality in the 
long term. Research is being carried out on the role of inflammatory mediators in the clinical manifestation of cardiogenic 
shock. Mechanical support devices also show promise in the future. 
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balloon counterpulsation, coronary artery bypass grafting. 
INTRODUCTION 
  Cardiogenic shock is the most common cause of death in 
patients with acute myocardial infarction (AMI) [1-9] and 
has a frequency of around 7-10% [1, 2, 10]. It continues to 
cause significant mortality despite advances in pharmacol-
ogical, mechanical and reperfusion endeavors.  
DEFINITION 
  Cardiogenic shock is defined as a systolic blood pressure 
of less than 90 mmHg for at least 30 minutes, which is sec-
ondary to myocardial dysfunction. It is associated with clini-
cal signs of hypoperfusion, which include decreased urine 
output, altered mental status and peripheral vasoconstriction. 
It is usually unresponsive to fluids, an important differentiat-
ing quality from other types of shock. However, it frequently 
responds to inotropes. The cardiac index (CI) and the pul-
monary capillary wedge pressure (PCWP) are usually less 
than 2.2 l/min/m
2 and greater than 15 mmHg respectively 
[11].  
INCIDENCE 
  The incidence within the community over a 23-year pe-
riod (1975-1997) was found to be 7.1% [6]. In the, Global 
Utilization of Streptokinase and Tissue Plasminogen Activa-
tor for Occluded Arteries (GUSTO-1) trial [7], the incidence 
of cardiogenic shock was likewise 7.2%, and consistent with 
other studies [12-14]. However, it is difficult to assess the 
actual number, as a certain proportion of patients die before 
reaching the hospital and cannot be categorized as having 
cardiogenic shock [2, 12, 14]. Over the years, there has been 
little decrease in the time to present to the hospital [15].  
  A larger number of patients develop shock after reaching 
the hospital. This highlights an important fact that medical 
contact may have been established before shock develop-
ment and opens the door to its possible prevention. In the  
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GUSTO trial, 11% of patients had shock on presentation 
while 89% of patients subsequently developed shock [7]. 
Similarly in the SHould we emergently revascularise Oc-
cluded Coronaries for cardiogenic shock? (SHOCK) trial 
registry, more than half the patients developed shock within 
a day of presenting to the hospital [4]. Early shock, defined 
as occurring in less than 24 hours, was found in 74.1% of 
patients in a recent study [16]. In addition, it has been ob-
served that there is a slight increase in the number of deaths 
among patients who present with early shock [17]. 
  Despite emerging innovative treatments, in-hospital mor-
tality in patients with cardiogenic shock continues to be as 
high as 70-80% [1, 2]. Other studies have quoted mortality 
rates of around 50% to 80% [4]. A study carried out at a ter-
tiary care hospital in Pakistan had an in-hospital mortality 
rate of 55% [18]. In another study, the overall in-hospital 
mortality was high (63%) but was found to reduce (P=0.004) 
over time from 1992 to 1997. This was partially attributed to 
the greater use of revascularization procedures, which are 
known to improve outcomes [19]. 
  Cardiogenic shock seems to occur with a greater fre-
quency amongst patients with ST-segment elevation myo-
cardial infarction (STEMI). It was observed that shock de-
veloped in 7.5% of patients with STEMI [2, 7] and in 2.5% 
of patients with non-ST-segment elevation myocardial in-
farction (NSTEMI) [20]. In another study, 4.2% of patients 
with STEMI and 2.5% of patients with NSTEMI had cardio-
genic shock. A significant delay precedes shock develop-
ment in patients with NSTEMI [21]. The underlying reason 
may be the rapid cell necrosis that takes place in STEMI 
contrasting with a slower cell loss in NSTEMI. Thus, the 
highest creatine kinase (CK) level is found in STEMI as 
compared to NSTEMI [20]. 
  Diabetics are twice as likely to develop cardiogenic 
shock as non-diabetics with AMI. However, the prognosis of 
cardiogenic shock is similar in both groups of patients [22].  
ETIOLOGY 
  Left ventricular dysfunction (LVD) is the most frequent 
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lighted that LVD was the main etiology [4, 24], occurring in 
74.5% of patients. This was followed by acute mitral regur-
gitation (8.3%), ventricular septal rupture (4.6%), isolated 
right ventricular shock (3.4%), tamponade or cardiac rupture 
(1.7%), and other causes (8%) (Table 1). 
Table 1.  Causes of Cardiogenic Shock 
Acute Myocardial Infarction 
 Left  ventricular  dysfunction 
  Acute mitral regurgitation 
 Ventricular  septal  rupture 
 Right  ventricular  shock 
 Cardiac  Tamponade 
 Cardiac  Rupture 
Infarctions were located anteriorly in most of the patients 
(55%) in the SHOCK trial registry [4, 24].   While  46%  of 
the infarctions were inferior, 21% were posterior, and 50% 
were in multiple locations. Other studies have found similar 
results [25]. Around 60% of patients had triple vessel disease 
while left main disease was encountered in 20% [26]. The 
left anterior descending artery (LAD) was found to be the 
most frequently involved artery unrelated to the time of 
shock onset [17]. Thus, severe arterial disease precedes 
shock development. 
  The median time from the onset of infarction to shock 
development was 5.6 hours [4]. In the SHOCK trial registry 
it was found to be 6.2 hr [16]. Certain characteristics (Table 
2) such as, being elderly, diabetic or having anterior infarc-
tion predispose patients with myocardial infarction to de-
velop shock [1, 27-29]. Some other factors include presence 
of previous infarction, peripheral vascular disease, cere-
brovascular disease, reduced ejection fractions and larger 
infarctions [27-28]. Age was most strongly associated with 
shock. In another study, age, systolic blood pressure, heart 
rate and Killip class at presentation contributed to more than 
85% of the predictive data for increased risk of shock [30]. 
Clinicians should be more vigilant in such cases and monitor 
these patients more frequently and aggressively. 
Table 2.  Predisposing Factors for Cardiogenic Shock 
Age 
Sysolic blood pressure 
Heart rate 
Killip class 
Diabetes 
Anterior infarction 
Previous infarction 
Peripheral vascular disease 
Reduced ejection fraction 
Large infarctions 
Cardiac power 
  Cardiac power was predicated to be the strongest inde-
pendent hemodynamic factor associated with mortality in 
patients admitted to hospitals with cardiogenic shock. It was 
also observed that older age and females had reduced cardiac 
power [31]. 
PATHOPHYSIOLOGY 
  Ischemia due to decreased coronary perfusion leads to 
muscle hypoxia and necrosis which compromises myocardial 
contractility. This leads to decreased cardiac output and a 
subsequent drop in the arterial blood pressure. Simultane-
ously, the body’s sympathetic system responds to the re-
duced blood pressure by increasing vasoconstriction. The 
hormonal system is also activated leading to salt and water 
retention. This has a detrimental role, as the coronary perfu-
sion is further compromised. A vicious cycle is thus created 
and it leads to decreased perfusion at the tissue level. Lactic 
acidosis and hypoxia eventually sets in, which further com-
promise the myocardial contractility until the arterial blood 
pressure is not maintained to a level needed to sustain life. 
MANAGEMENT  
Assessment 
  Cardiogenic shock is an emergency and it needs rapid 
diagnosis and institution of therapy. Improved long-term 
outcomes require immediate diagnosis and management and 
if needed, transfer to a tertiary care hospital [32]. 
  History will usually reveal symptoms of a preceding 
AMI. A diagnosis of cardiogenic shock is made when myo-
cardial dysfunction is observed in the absence of other 
causes such as hemorrhage, sepsis, pulmonary embolism, 
tamponade, aortic dissection, and preexisting valvular dis-
ease [32]. On a physical exam (Table 3), the patient may be 
cyanotic with cold extremities and pulses are usually rapid 
and faint. If LVD is the etiology, then jugular venous disten-
tion (JVD) and rales in the lung field due to pulmonary con-
gestion are observed. If right ventricular failure is the under-
lying cause then JVD and kussmaul’s sign is present and 
pulmonary rales are not found. Other findings include distant 
heart sounds and the presence of third and fourth heart 
sounds. Mitral regurgitation or a VSD can lead to a new sys-
tolic murmur. Arrhythmias are a frequent occurrence and 
need immediate attention.  
Table 3.  Clinical Signs of Cardiogenic Shock 
Cyanosis 
Rapid and/or faint pulses 
Jugular venous distension 
Cold extremities 
Pulmonary rales 
Distant heart sounds 
Third and fourth heart sounds 
Decreased urine output 
Altered mental status 
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  64% of patients in the SHOCK trial registry, presented 
with hypotension and signs of hypoperfusion such as tachy-
cardia, altered sensorium, decreased urine output and cool 
extremities. These patients also had signs of pulmonary con-
gestion [33]. A smaller proportion of patients (28%) experi-
enced shock with no pulmonary congestion, which is also 
known as the silent lung syndrome. However, clinicians 
should be wary and refrain from incorrectly associating ab-
sence of pulmonary congestion with decreased risk [33]. 
Thus, signs of hypoperfusion alone are mortality indicators 
regardless of the presence or absence of pulmonary conges-
tion [33]. Similarly, the GUSTO-I study observed increased 
mortality at 30 days if oliguria, cold extremities or altered 
sensorium were found to be present [34]. Another study also 
ascertained oliguria and cold extremities as independent and 
strong mortality predictors [20]. Thus, the initial clinical 
assessment of a patient is important in determining the future 
prognosis. 
Diagnosis 
  Tools that facilitate diagnosis (Table 4) include an elec-
trocardiogram (ECG), cardiac enzymes, chest X ray, arterial 
bloodgases(ABG),electrolytes,complete blood count (CBC) 
and/or a coagulation profile [35]. Invasive hemodynamic 
monitoring may be required but is not a necessity. Bedside 
echocardiography plays a vital role in assessing the possible 
contributing causes [36, 37]. It can be used to quickly rule 
out or diagnose mitral regurgitation, ventricular septal or free 
wall tear, tamponade or a pericardial effusion so that emer-
gent intervention can be instituted. 
Table 4.  Diagnostic Evaluation of Cardiogenic Shock 
CBC
Electrolytes 
Cardiac enzymes 
Coagulation profile 
ABG 
CXR
ECG 
Echocardiogram 
Right heart catheterization 
CBC=Complete blood count 
ABG=arterial blood gases 
CXR=chest x-ray 
ECG=elctrocardiogram 
  There is controversial evidence regarding right heart 
catheterization. One study claimed improved outcomes [38] 
by using this invasive procedure while increased mortality 
was observed in a different study [39]. 
TREATMENT 
Initial Stabilization 
  Aspirin and heparin constitute the first line of treatment. 
Fluids may need to be given in order to rule out hypovolemic 
shock. These need to be instituted with continuous monitor-
ing of clinical signs, such as urine output, blood pressure and 
heart rate. In right ventricular failure, fluid support is re-
quired and nitrates and morphine should be avoided, as they 
tend to increase hypotension. Oxygen should be given 
through a face mask or if the need arises, airway should be 
secured and mechanical ventilation started. Arrhythmias are 
a frequent occurrence and sustained tachyarrhythmias need 
to be converted electrically so as to avoid further compro-
mise of the cardiac output. Bradyarrhythmias may require 
atropine or temporary pacing [35]. 
  Morphine reduces sympathetic stimulation and should be 
given for pain relief. It also decreases the preload and de-
compresses the left ventricle [35]. Nitroglycerine, a venodi-
lator, has limited use in cardiogenic shock. It is important to 
maintain the mean arterial blood pressure above 90 mmHg. 
For this purpose, inotropes and vasopressors like dopamine 
and catecholamines may be required. Dopamine, an inotrope 
and a vasopressor, is preferred initially. Another alternative 
is dobutamine but its use may produce vasodilation and lead 
to hypotension [32]. In some situations, a combination of 
dopamine and dobutamine are more beneficial than the use 
of either agent alone [40]. Persistently low systolic blood 
pressures with values such as 70 mmHg require addition of 
more drugs such as norepinephrine. Pressor agents should be 
used carefully as they increase the heart rate and may trigger 
arrythmias. Diuretics are added if pulmonary congestion is 
present to help in increasing the oxygenation [32]. Electro-
lyte imbalances and metabolic acidosis need immediate 
treatment. Nitrates, b-blockers, and angiotensin-converting 
enzyme inhibitors help to improve outcomes after myocar-
dial infarction [41]. However, beta-blockers can deteriorate 
the condition and are generally avoided in shock. 
SUPPORTIVE MEASURES 
Intra-Aortic Balloon Pump (IABP) 
  Intra-aortic balloon pump (IABP) is required for stabiliz-
ing patients before reperfusion therapies. It increases coro-
nary blood flow during diastole and decreases the afterload 
by lowering the systemic vascular resistance during systole. 
However, if there is severe coronary stenosis, there is little 
improvement in coronary perfusion [42]. The GUSTO-1 trial 
[43], observed a decreased mortality rate at 30 days in pa-
tients treated with IABP (46%) as compared to those who 
did not receive this treatment (60%, P = 0.11). Similarly, in 
the SHOCK trial, patients who received treatment with IABP 
had reduced rates of mortality (50%) within hospital, versus 
those who did not have IABP placement (72%, P<0.0001) 
[44]. It was used in both the arms of the study: medical man-
agement and revascularisation. 
  The American College of Cardiology/American Heart 
Association (ACC/AHA) STEMI guidelines [45] give a class 
I recommendation for use of IABP when cardiogenic shock 
cannot be managed on medications alone. This allows stabi-
lization for angiography and revascularization procedures. 
  Thus, in hospitals where emergent revascularization is 
not available, it is more appropriate to proceed with fibri-
nolytic therapy and IABP while arrangements are made for 
percutaneous transluminal coronary angioplasty (PTCA) or 
coronary artery bypass graft (CABG). This might be a more 
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where there may be unavailability of immediate revasculari-
zation facilities in hospitals. 
Reperfusion Strategies  
Fibrinolytic Therapy 
  Fibrinolytic therapy, when used in patients with AMI 
without shock, decreases shock onset [7, 46-49]. This is a 
vital fact, as it is known that shock development occurs after 
six hours of presentation to the hospital [4, 7, 13, 24]. These 
six hours are crucial for institution of treatment and can play 
a role in the prevention of cardiogenic shock.  
  In some trials, outcomes have been found to be similar 
with the use of streptokinase versus placebo and between 
streptokinase and tissue plasminogen activator [7, 12, 13]. 
However, in the SHOCK registry, patients receiving fibri-
nolytic therapy had lower mortality rates (54%) in the hospi-
tal versus those who did not receive fibrinolytic therapy 
(64%, P=0.005) [44]. But confounding factors may have 
been involved. 
  The outcome of treatment with fibrinolytics is associated 
with the degree of reperfusion [50, 51] but in patients with 
cardiogenic shock it is reduced [25, 51, 52] due to decreased 
coronary perfusion. In conclusion, the use of fibrinolytics 
does not increase survival in patients with an ongoing car-
diogenic shock. 
  Hospitals lacking revascularization capabilities may pur-
sue IABP and fibrinolytic therapy while making arrange-
ments to transfer to hospitals with revascularisation capabili-
ties [44].  
Percutaneous Coronary Intervention  
  In the GUSTO-1 trial, a reduced mortality rate (43%) was 
observed at 30 days with successful PTCA as compared to 
those without PTCA (61%) as a mode of treatment [21]. The 
Swiss Multicenter Trial of Angioplasty Shock (SMASH) 
trial [53, 54] also showed decreased mortality rates in pa-
tients treated invasively rather than medically. However, it 
did not reach statistical significance. The SHOCK trial [5] 
also compared emergent revascularization versus immediate 
medical stabilization. The latter involved use of fibrinolytic 
therapy, inotropic and vasopressor agents. IABP was used 
quite frequently (86%) in patients. The revascularization arm 
was further dichotomized: 64% of patients underwent PCI 
and 36% had coronary artery bypass surgery. However, the 
mortality rates in the two groups of revascularization and 
medical treatment were not found to be statistically signifi-
cant at 30 days (46.7% vs. 56.0%, respectively, P = 0.11), 
but by 6-months there was some divergence and significantly 
increased survival rates were observed in patients treated 
with revascularization (50.3% vs. 63.1%, P=0.027). Thus 
long-term benefits emerged subsequently and a significant 
mortality reduction was observed at 6 months consistent with 
13 lives saved per 100 patients treated [5]. Diabetics have 
similar improved outcomes as non-diabetics, if revasculari-
zation is used, as observed in both the SHOCK Trial Regis-
try and the SHOCK trial [55]. Furthermore, after one year, 
survival was 46.7% for patients in the revasularisation group 
compared with 33.6% in the medically treated group 
(P<0.03) [56]. Thus, significant long-term mortality benefits 
are observed with emergent revascularisation. Consistent 
with the above data, mortality due to cardiogenic shock in 
AMI has been found to be lower in hospitals with catheteri-
zation facilities than in hospitals without such facilities [57].  
  Analysis of the subgroup constituting patients less than 
75 years, underscores a marked interaction between patient 
age and treatment outcome. A decrease in mortality by 15 % 
at 30 days is observed in patients less than 75 years of age 
treated by revascularisation. At 6 months, the reduction in 
mortality was found to be 20%. However, in patients 75 
years and above an increase in mortality by 22% was ob-
served when patients were treated with revascularization 
rather than initial medical stabilization [5].  
  The outcome of PTCA is important in determining the 
survival of patients. The degree of reperfusion in the infarct 
related artery is associated with outcomes [58]. In the recent 
SHOCK trial, it was observed that the 30-day mortality rate 
was reduced with successful angioplasty (38%) as compared 
to patients with unsuccessful angioplasty (79%) [5]. How-
ever, reperfusion is lower in patients with cardiogenic shock 
[59, 60]. Patients with shock have comparatively less suc-
cessful reperfusion rates (54% to 100%) with PTCA in the 
infarct-causing artery, than in patients without shock [61-71].  
  There are some indications that stents are an important 
ancillary part of cardiogenic shock management. [72]. In the 
Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor 
Suppression Using Integrilin Therapy (PURSUIT) trial, use 
of eptifibatide had no consequence on the development of 
shock, in patients with non-ST elevation acute coronary syn-
dromes, but a mortality reduction from 73.5% to 58.5% 
(P=0.03) was seen [73]. Lack of stent and glycoprotein 
IIb/IIIa usage has been observed as predictors of mortality in 
a recent study. Six predictors of mortality in patients present-
ing with shock included age, female gender, creatinine lev-
els, total blockage of the left anterior descending artery 
(LAD), absence of stent use, absence of glycoprotein IIb/IIIa 
inhibitor use, during PCI. These were all found to be statisti-
cally significant. A second analysis carried out with variables 
identified at the time of initial presentation found gender, 
age, renal insufficiency, and total occlusion of the left ante-
rior descending coronary artery to be significant [74].  
  Thus, in conclusion, the current American College of 
Cardiology/American Heart Association (ACC/AHA) guide-
lines recommend (class I) early revascularisation strategy for 
patients < 75 years of age with cardiogenic shock [75]. It is 
also recommended that patients especially less than 75 years 
of age should be promptly transferred to tertiary care hospi-
tals where revascularization can be performed [56]. 
Surgical Intervention 
  Patients in cardiogenic shock undergoing emergent coro-
nary artery bypass surgery have mortality rates of around 
25% to 60% [76]. In the SHOCK trial, 36% of the patients 
randomized to revascularization in that study were treated 
surgically [5]. Such patients were more likely to have left 
main disease, 3-vessel disease and diabetes than those treated 
with PCI. However, similar survival rates were observed in 
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57.4% in the CABG group at 30 days (P=0.86). Likewise 
after one year, the rates were 51.9% (PCI) versus 46.8% 
(CABG), respectively, (P=0.71). [77].  
  Some retrospective studies quote improved outcomes 
when CABG is used as an emergency procedure for AMI 
and cardiogenic shock [78-81]. In patients with left main or 
triple-vessel disease, stabilization by IABP and immediate 
activation of the surgery team should be sought, as CABG 
may be the more desired procedure in such patients to estab-
lish complete revascularization [5]. 
  Patients presenting with additional mechanical complica-
tions such as acute mitral regurgitation due to papillary mus-
cle rupture or LV free wall or septal rupture need surgery for 
survival, however, the outcome in such patients is much 
worse [35]. Ventricular septal rupture has a high in-hospital 
mortality of around 87% as observed in the SHOCK registry. 
Patients undergoing surgery for ventricular septal rupture 
have a survival rate of 19% [82]. 
  Diagnosis of shock heralds a high mortality rate of 
around 50%, regardless of the benefits of early PCI or 
CABG. Around 50% of these deaths occur in the first 2 days 
[23, 83]. 
Other Mechanical Supports 
  IABP is useful in providing mechanical support during 
shock. It has been observed that cardiac index can indicate if 
potential benefit can be derived from IABP. The use of IABP 
has better outcomes when used in patients with a cardiac 
index higher than 1.2 L/min/m
2 and a systemic vascular re-
sistance less than 2100 dynes/sec/cm
–5. However, if the car-
diac index is lower than 1.2 L/min/m
2, outcome is poor even 
if IABP is used. In such cases other support devices may be 
required [84]. 
  Extracorporeal life support (ECLS) has been utilized in 
cases of severe cardiac or pulmonary failure [85]. Percutane-
ous cardiopulmonary bypass can also provide support and 
can be performed at the bedside through the femoral artery 
and vein [86]. These two devices however, do not help in 
unloading the left ventricle. 
  Biventricular assist devices, can serve as a bridge to car-
diac transplantation. This has been found to have a success 
rate of around 59% [87]. Experimental percutaneous LV 
assist devices help to unload the left ventricle [88] and pre-
sent another option.  
New Pharmacological Agents  
  During the development of cardiogenic shock, the body 
may launch a systemic inflammatory response, which has led 
to investigations on inflammatory mediators. Chemical 
agents are being investigated for their contribution in cardio-
genic shock. Nitric oxide production has also been thought to 
play a role in the development of cardiogenic shock and 
some studies indicate that inhibition of nitric oxide produc-
tion may improve outcomes [89-91].  
  Thus, support systems in the form of mechanical devices 
and medications will have an increasing role in the future as 
part of our management strategies. 
CONCLUSION 
  Cardiogenic shock due to AMI continues to be the main 
cause of death in these patients. Immediate diagnosis and 
management is required. There are two strategies in treating 
cardiogenic shock: medical versus invasive. If institutions 
lack revascularization facilities, fibrinolytic therapy and 
IABP should be used while provisions are made for invasive 
treatment. However, current guidelines favor an invasive 
approach. Prognosis is established by the outcome of revas-
cularization regardless of the procedure used, such as PCI or 
surgery [92]. Newer devices are being developed for me-
chanical support. Inhibitors of nitric oxide have also shown 
favorable outcomes. These newer therapies may help in de-
creasing the significant mortality of cardiogenic shock in the 
future. 
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